Incyte Corp logo

Incyte Corp

11
NAS:INCY (USA)   Ordinary Shares
$ 60.59 -0.32 (-0.53%) 10:08 PM EST
22.86
P/B:
2.62
Market Cap:
$ 13.60B
Enterprise V:
$ 9.99B
Volume:
1.37M
Avg Vol (2M):
1.62M
Also Trade In:
Volume:
1.37M
Avg Vol (2M):
1.62M
PE Ratio PS Ratio PB Ratio Price-to-FCF Market Cap
Current and historical daily PE Ratio for Incyte Corp ( ) from 1993 to Feb 25 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Incyte stock (INCY) PE ratio as of Feb 25 2024 is 22.86. More Details

Incyte Corp (INCY) PE Ratio (TTM) Chart

To

Incyte Corp (INCY) PE Ratio (TTM) Historical Data

Total 1237
  • 1
  • 2
  • 3
  • 4
  • 5
  • 6
  • 14
Incyte PE Ratio (TTM) Historical Data
Date PE Ratio (TTM) Data Date PE Ratio (TTM) Data
2024-02-25 22.9 2023-12-19 32.8
2024-02-23 22.9 2023-12-18 32.1
2024-02-22 23.0 2023-12-15 33.0
2024-02-21 22.8 2023-12-14 33.8
2024-02-20 22.2 2023-12-13 34.0
2024-02-16 21.9 2023-12-12 32.7
2024-02-15 22.3 2023-12-11 30.2
2024-02-14 21.9 2023-12-08 28.9
2024-02-13 22.4 2023-12-07 29.2
2024-02-12 21.8 2023-12-06 29.3
2024-02-09 21.8 2023-12-05 29.0
2024-02-08 21.6 2023-12-04 29.1
2024-02-07 21.6 2023-12-01 28.6
2024-02-06 22.5 2023-11-30 28.8
2024-02-05 21.9 2023-11-29 28.3
2024-02-02 22.0 2023-11-28 27.9
2024-02-01 22.3 2023-11-27 28.0
2024-01-31 22.2 2023-11-24 28.4
2024-01-30 22.4 2023-11-22 28.3
2024-01-29 22.8 2023-11-21 28.2
2024-01-26 22.9 2023-11-20 28.9
2024-01-25 23.0 2023-11-17 28.7
2024-01-24 23.0 2023-11-16 28.6
2024-01-23 23.4 2023-11-15 29.1
2024-01-22 23.2 2023-11-14 28.9
2024-01-19 23.2 2023-11-13 28.1
2024-01-18 23.1 2023-11-10 27.8
2024-01-17 23.2 2023-11-09 27.8
2024-01-16 23.1 2023-11-08 28.6
2024-01-12 23.7 2023-11-07 28.9
2024-01-11 23.8 2023-11-06 28.9
2024-01-10 24.2 2023-11-03 29.0
2024-01-09 24.3 2023-11-02 28.6
2024-01-08 24.8 2023-11-01 28.8
2024-01-05 24.6 2023-10-31 28.5
2024-01-04 25.1 2023-10-30 27.6
2024-01-03 24.7 2023-10-27 27.8
2024-01-02 24.7 2023-10-26 28.7
2023-12-29 23.7 2023-10-25 28.7
2023-12-28 23.7 2023-10-24 29.1
2023-12-27 33.2 2023-10-23 29.1
2023-12-26 33.1 2023-10-20 29.2
2023-12-22 33.3 2023-10-19 29.4
2023-12-21 32.6 2023-10-18 30.1
2023-12-20 32.1 2023-10-17 30.3

Incyte Corp (INCY) PE Ratio (TTM) Comparison

Company Market Cap(Mil) PE Ratio (TTM)

Business Description

Business Description

Description
Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.